Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial

OBJECTIVE: To directly compare the efficacy and safety of a fixed-ratio combination, of insulin glargine 100 units/mL and the glucagon-like peptide 1 receptor agonist lixisenatide (iGlarLixi), with those of a premix insulin analog, biphasic aspart insulin 30 (30% insulin aspart and 70% insulin aspar...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenstock, Julio, Emral, Rifat, Sauque-Reyna, Leobardo, Mohan, Viswanathan, Trescolí, Carlos, Al Sifri, Saud, Lalic, Nebojsa, Alvarez, Agustina, Picard, Pascaline, Bonnemaire, Mireille, Demil, Nacima, McCrimmon, Rory J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Emerging Therapies: Drugs and Regimens
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740944/
https://www.ncbi.nlm.nih.gov/pubmed/34183429
http://dx.doi.org/10.2337/dc21-0393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740944/
https://www.ncbi.nlm.nih.gov/pubmed/34183429
http://dx.doi.org/10.2337/dc21-0393

Ejemplares similares